摘要
目的:观察地衣芽孢杆菌活菌胶囊胶囊联合注射用英夫利西单抗治疗溃疡性结肠炎患者的效果。方法:回顾性分析2022年6月至2023年6月该院收治的100例溃疡性结肠炎患者的临床资料,按照治疗方法不同将其分为对照组与观察组各50例。对照组采用注射用英夫利西单抗治疗,观察组在对照组基础上联合地衣芽孢杆菌活菌胶囊治疗。比较两组临床疗效,治疗前后血清炎性因子[C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)]水平、肠道菌群(粪肠球菌、大肠埃希菌、双歧杆菌、乳酸杆菌)数量,以及不良反应发生率。结果:观察组治疗总有效率为94.00%(47/50),高于对照组的80.00%(40/50),差异有统计学意义(P<0.05);治疗后,两组CRP、TNF-α、IL-6水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组粪肠球菌、大肠埃希菌数量均少于治疗前,且观察组少于对照组,两组双歧杆菌、乳酸杆菌数量均多于治疗前,且观察组多于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:地衣芽孢杆菌活菌胶囊联合注射用英夫利西单抗治疗溃疡性结肠炎患者可提高治疗总有效率,改善肠道菌群水平,以及降低血清炎性因子水平,效果优于单纯注射用英夫利西单抗治疗。
Objective:To observe effects of Living Bacillus licheniformis combined with Infliximab for injection in treatment of patients with ulcerative colitis.Methods:The clinical data of 100 patients with ulcerative colitis admitted to this hospital from June 2022 to June 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,50 cases in each group.The control group was treated with Infliximab for injection,while the observation group was treated with Bacillus licheniformis on the basis of that of the control group.The clinical efficacy,the levels of serum inflammatory factors[C-reactive protein(CRP),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)],the number of intestinal flora(Enterococcus faecalis,Escherichia coli,Bifidobacterium,Lactobacillus)before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 94.00%(47/50),which was higher than 80.00%(40/50)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CRP,TNF-αand IL-6 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the con trol group,and the differences were statistically significant(P<0.05).After the treatment,the number of Enterococcus faecalis and Escherichia coli in the two groups was less than those before the treatment,and that in the observation group was less than that in the control group;the number of Bifidobacterium and Lactobacillus in the two groups was more than those before the treatment,and that in the observation group was more than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Living Bacillus licheniformis combined with Infliximab for injection can improve the total effective rate of treatment,improve the levels of intestinal flora,and reduce the levels of serum inflammatory factors in the patients with ulcerative colitis.Moreover,it is superior to simple Infliximab for injection treatment.
作者
杨以良
汪静
石保平
李士坤
YANG Yiliang;WANG Jing;SHI Baoping;LI Shikun(Department of Gastroenterology of Xinyang Central Hospital,Xinyang 464000 Henan,China)
出处
《中国民康医学》
2025年第14期40-42,46,共4页
Medical Journal of Chinese People’s Health
